What one share of Neuphoria Therapeutics holds
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs.
Neuphoria Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.27 |
|---|---|
| Profit | −$3.06 |
| Cash and investments | $3.67 |
| Book value | $4.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$18.62 | — | — | — | $15.84 |
| 2025 | $9.64 | −$0.23 | — | — | — | $9.60 |
| 2026 | $0.27 | −$3.06 | — | — | — | $4.55 |
Common questions about Neuphoria Therapeutics
How much does one share of Neuphoria Therapeutics earn?
Over its latest fiscal year, Neuphoria Therapeutics lost $3.06 for each share on $0.27 of sales.
Does Neuphoria Therapeutics pay a dividend?
Neuphoria Therapeutics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Neuphoria Therapeutics’s book value per share?
Neuphoria Therapeutics’s book value is $4.55 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Neuphoria Therapeutics have?
Each share of Neuphoria Therapeutics has $3.67 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.